Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder

被引：155

作者：

Drutz H.P. ^{[1
,6
]}

Appell R.A. ^{[2
]}

Gleason D. ^{[3
]}

Klimberg I. ^{[4
]}

Radomski S. ^{[5
]}

机构：

[1] University of Toronto, Mount Sinai Hospital, Toronto, Ont.

[2] Cleveland Clinic Foundation, Cleveland, OH

[3] Urological Assoc. of S. Arizona, Tucson, AZ

[4] Urology Center of Florida, Ocala, FL

[5] Toronto Western Hospital, Toronto, Ont.

[6] Section of Urogynecology, University of Toronto, Mount Sinai Hospital, Toronto, Ont. M5G 1X5

来源：

International Urogynecology Journal | 1999年 / 10卷 / 5期

关键词：

Comparative study; Overactive bladder; Oxybutynin; Tolterodine;

D O I：

10.1007/s001929970003

中图分类号：

学科分类号：

摘要：

This study compared the clinical efficacy (determined from micturition diaries) and safety of 12 weeks' treatment with either tolterodine 2 mg twice daily, oxybutynin 5 mg three times daily or placebo in patients with an overactive bladder. A total of 277 patients were randomized and treated at 25 centers. Both tolterodine and oxybutynin significantly increased volume voided/micturition compared to placebo. Both treatment groups evoked greater decreases in micturitions per 24 hours and incontinence episodes per 24 hours compared to placebo; however, only tolterodine was significantly better than placebo in reducing micturition frequency. Tolterodine and oxybutynin were equivalent in their effectiveness. Tolterodine was significantly better tolerated than oxybutynin when adverse events (particularly frequency and intensity of dry mouth), dose reduction and patient withdrawals were considered. Oxybutynin is an effective drug whose frequent adverse effects limit its clinical usefulness. Tolterodine has equivalent efficacy to oxybutynin, but with less severe adverse effects. This will allow patients to receive more effective treatment for their condition, with better compliance.

引用

页码：283 / 289

页数：6

共 17 条

[1]

Andersson K.-E., Current concepts in the treatment of disorders of micturition, Drugs, 35, pp. 477-494, (1988)

[2]

Yarker Y.E., Goa K.L., Fitton A., Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability, Drugs Aging, 6, pp. 243-262, (1995)

[3]

Appell R.A., Oxybutynin. The clinical experience, Contemp Urol, 3, pp. 60-67, (1991)

[4]

Thuroff J., Bunke B., Ebner A., Et al., Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin versus propantheline versus placebo, J Urol, 145, pp. 813-817, (1991)

[5]

Ouslander J.G., Blaustein J., Connor A., Orzeck S., Yong C.L., Pharmacokinetics and clinical effects of Oxybutynin in geriatric patients, J Urol, 140, pp. 47-50, (1988)

[6]

Kelleher C.J., Cardozo L.D., Khullar V., Salvatore S., Hill S., Anticholinergic therapy: The need for continued surveillance, Neurourol Urodyn, 13, pp. 432-433, (1994)

[7]

Nilvebrant L., Hallen B., Larsson G., Tolterodine: A new bladder selective, muscarinic receptor antagonist: preclinical pharmacological and clinical data, Life Sci, 60, pp. 1129-1136, (1997)

[8]

Nilvebrant L., Andersson K.-E., Gillberg P.-G., Stahl M., Sparf B., Tolterodine - A new bladder-selective antimuscarinic agent, Eur J Pharmacol, 327, pp. 195-207, (1997)

[9]

Rentzhog L., Stanton S.L., Cardozo L., Nelson E., Fall M., Abrams P., Efficacy and safety of tolterodine in patients with detrusor instability: A dose-ranging study, Br J Urol, 81, pp. 42-48, (1998)

[10]

Zorzitto M.L., Holliday P.J., Jewett M.A., Herschorn S., Fernie G.R., Oxybutynin chloride for geriatric urinary dysfunction: A double-blind placebo-controlled study, Age Aging, 18, pp. 195-200, (1989)

← 1 2 →